King Pharmaceuticals (KG) Misses Q2 EPS by 103c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts KG Hot Sheet
Join SI Premium – FREE
King Pharmaceuticals (NASDAQ: KG) reported Q2 EPS of ($1.03). Revenue for the quarter came in at $6.7 million.
For earnings history and earnings-related data on King Pharmaceuticals (KG) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- Citizens Downgrades MNTN Inc (MNTN) to Market Perform
- JPMorgan Downgrades SPAR Group Ltd (SPPJ:SJ) (SGPPF) to Underweight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
